Product Description
JS207 is a recombinant humanized anti-PD-1/VEGF bispecific antibody self-developed by the Company, mainly used for the treatment of advanced malignant tumors. In view of the co-expression of VEGF and PD-1 in the tumor microenvironment, JS207 can simultaneously bind to PD-1 and VEGFA with high affinity, block the binding of PD-1 to PD-L1 and PD-L2 while blocking the binding of VEGF to the VEGF receptor. JS207 has the efficacy properties of both immunotherapeutic drugs and anti-angiogenic drugs, and can utilize the synergistic effects of immunotherapy and anti-angiogenesis to achieve better anti-tumor activity. (Sourced from: https://www1.hkexnews.hk/listedco/listconews/sehk/2023/0619/2023061900918.pdf)
Mechanisms of Action: PD-1 Inhibitor, VEGF Inhibitor
Novel Mechanism: No
Modality: Bispecific Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Shanghai Junshi Bioscience
Company Location: Asia Pacific
Company Founding Year: 2012
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, China
Active Clinical Trial Count: 22
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Hepatocellular Carcinoma
Phase 2: Colorectal Cancer|Lung Cancer|Non-Small-Cell Lung Cancer|Oncology Solid Tumor Unspecified|Small Cell Lung Cancer|Triple Negative Breast Cancer
Phase 1: Oncology Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06944470 |
JS207-005-II-NSCLC | P2 |
Active, not recruiting |
Small Cell Lung Cancer|Non-Small-Cell Lung Cancer |
2027-04-30 |
2026-07-28 |
Primary Endpoints |
|
NCT06885385 |
JS207-007-II-CRC | P2 |
Recruiting |
Colorectal Cancer |
2026-11-27 |
2025-06-25 |
Primary Endpoints|Start Date|Treatments|Trial Status |
|
NCT06868836 |
JS207-002-II-NSCLC | P2 |
Recruiting |
Non-Small-Cell Lung Cancer |
2026-09-04 |
2026-05-19 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments |
|
NCT06022250 |
JS207-001-I | P1 |
Active, not recruiting |
Oncology Unspecified |
2026-04-08 |
2026-07-03 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
NCT07876557 |
JS212-009-II-BC | P2 |
Not yet recruiting |
Triple Negative Breast Cancer |
2027-12-31 |
2026-10-16 |
||
NCT06954467 |
JS207-006-II-HCC | P2 |
Recruiting |
Hepatocellular Carcinoma |
2027-12-31 |
2025-07-03 |
Primary Endpoints|Start Date|Treatments|Trial Status |
|
NCT07309276 |
JS212-002-II-LC | P2 |
Recruiting |
Lung Cancer |
2027-11-30 |
2026-05-19 |
||
NCT06571422 |
JS125-001-I | P1 |
Active, not recruiting |
Oncology Solid Tumor Unspecified |
2026-12-15 |
2026-07-08 |
||
NCT07480733 |
JS212-004-II | P2 |
Recruiting |
Oncology Solid Tumor Unspecified |
2027-11-30 |
2026-05-30 |
Patient Enrollment|Primary Endpoints|Treatments |
|
CTR20250831 |
CTR20250831 | P2 |
Recruiting |
Colorectal Cancer |
None |
2025-06-22 |
Patient Enrollment|Start Date|Treatments|Trial Status |
|
CTR20251292 |
CTR20251292 | P2 |
Recruiting |
Non-Small-Cell Lung Cancer |
None |
2025-10-05 |
Patient Enrollment|Start Date|Treatments|Trial Status |
|
CTR20251351 |
CTR20251351 | P2 |
Active, not recruiting |
Hepatocellular Carcinoma |
None |
2026-08-30 |
Patient Enrollment|Treatments|Trial Status |
|
CTR20251713 |
CTR20251713 | P2 |
Recruiting |
Non-Small-Cell Lung Cancer |
None |
2025-07-06 |
Patient Enrollment|Start Date|Treatments|Trial Status |
|
CTR20251333 |
CTR20251333 | P2 |
Active, not recruiting |
Non-Small-Cell Lung Cancer |
None |
2026-07-20 |
Patient Enrollment|Start Date|Treatments|Trial Status |
|
NCT07823348 |
JS207-017-III-HCC | P3 |
Not yet recruiting |
Hepatocellular Carcinoma |
2029-10-30 |
2026-09-17 |
Primary Endpoints|Treatments |
|
CTR20232766 |
CTR20232766 | P1 |
Active, not recruiting |
Oncology Solid Tumor Unspecified |
None |
2025-09-28 |
Patient Enrollment|Treatments|Trial Status |
|
CTR20243655 |
CTR20243655 | P1 |
Active, not recruiting |
Oncology Solid Tumor Unspecified |
None |
2025-11-23 |
Patient Enrollment|Treatments|Trial Status |
|
NCT06953323 |
WJB001-002-I | P2 |
Recruiting |
Oncology Solid Tumor Unspecified |
2029-06-30 |
57% |
2026-03-27 |
Primary Endpoints |
NCT07045311 |
JS207-008-II-TNBC | P2 |
Recruiting |
Triple Negative Breast Cancer |
2028-03-22 |
2025-09-30 |
Primary Endpoints|Start Date|Treatments|Trial Status |
|
NCT06969027 |
JS207-010-II-NSCLC | P2 |
Active, not recruiting |
Non-Small-Cell Lung Cancer |
2027-12-31 |
2026-08-05 |
Primary Endpoints |
|
NCT07466160 |
7MW3711-CP202 | P2 |
Recruiting |
Small Cell Lung Cancer|Non-Small-Cell Lung Cancer |
2027-12-31 |
12% |
2026-03-13 |
Primary Endpoints|Treatments |
NCT07503756 |
JS212-005-II-CRC | P2 |
Recruiting |
Colorectal Cancer |
2027-12-30 |
2026-05-06 |
Primary Completion Date|Primary Endpoints|Start Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
10/16/2025 |
News Article |
Junshi Biosciences Announces FDA's Approval of IND Application for Phase 2/3 Clinical Study of JS207 for the Neoadjuvant Treatment of NSCLC Patients |